Tibulizumab
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research[1].
Product Specifications
CAS Number
1849636-24-3
Product Name Alternative
LY 3090106
UNSPSC
12352203
Target
Interleukin Related; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tibulizumab.html
Purity
98.86
Solubility
10 mM in DMSO
Smiles
[Tibulizumab]
Molecular Weight
(201.43 kDa)
References & Citations
[1]Robert J Benschop, et al. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs. 2019 Aug/Sep;11 (6) :1175-1190.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
IL-17
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-T888025-100MG 100 mg
2',4',6'-Trihydroxyacetophenone Monohydrate
Sign In for Pricing
View Details